There is a critical requirement for patient capital to play a catalytic role in funding development
India Health Fund, a Tata Trusts initiative, is collaborating with ACT, a non-profit venture philanthropy platform, to support Salcit Technologies in piloting Swaasa - an AI-led solution that can revolutionise the detection and early treatment of tuberculosis in India. Neetha Joy, Director - ACT For Health, Narayana Rao Sripada, Co-Founder - Salcit Technologies and Madhav Joshi, CEO, India Health Fund reveal more about the collaboration
Why is TB still a public health issue? Can you provide the incidence rate and reasons for the high incidence?
As per the Global TB Report 2021, the estimated incidence of all forms of TB in India for the year 2020 was 188 per 100,000 population. According to government statistics, 2021 witnessed a 19 per cent increase from the previous year in TB patients’ notification — the total number of incident TB patients (new and relapse) notified during 2021 were 19,33,381 as opposed to that 16,28,161 in 2020. In 2021, out of 2.23 crore patients screened for TB through government programmes, 73,772 patients were identified through ACF.
One major issue is that many TB cases go undetected or are misdiagnosed. Additionally, many people do not complete their treatment, leading to deterioration in their condition and the development of drug resistance. Finally, there is a lack of access to quality healthcare for TB patients, including accessibility to point-of-care diagnostics and availability of trained healthcare professionals, particularly in rural and underserved areas.
The high incidence rate of TB in India can be attributed to various factors, including:
- Limited access to healthcare, especially in underserved areas, can lead to delayed diagnosis and treatment, which can worsen the spread of the disease.
- Comorbidities like diabetes, HIV, tobacco smoking, and alcohol impact a person with TB in predisposition and severity.
- Poor living conditions and malnutrition increase the risk of TB.
- The emergence of drug-resistant TB strains is also a major concern as they require more expensive and prolonged treatment, which can be a challenge for the healthcare system.